Targeting Cancer Through Thymoquinone: From Molecular Mechanisms to Clinical Prospects

Nosayba Al-Damook1,2, Molham Sakkal1,2, Mostafa Khair3

  • 1College of Pharmacy, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates.

Insights

Thymoquinone (TQ), from black seed, shows potential in fighting cancer by inhibiting growth, promoting cell death, and overcoming chemoresistance. Further clinical studies are needed to explore its therapeutic benefits and improve delivery for cancer treatment.

Area of Science:

  • Natural compounds and cancer research
  • Pharmacology and therapeutic potential
  • Immunology and cancer therapy

Background:

  • Nigella sativa's active compound, thymoquinone (TQ), demonstrates significant anticancer properties in preclinical studies.
  • Cancer treatment faces challenges including chemoresistance and side effects, necessitating novel therapeutic strategies.
  • Understanding TQ's multifaceted mechanisms is crucial for its potential clinical application.

Purpose of the Study:

  • To review the diverse anticancer mechanisms of thymoquinone (TQ).
  • To explore TQ's potential in overcoming chemoresistance and enhancing conventional cancer therapies.
  • To identify challenges and suggest future directions for TQ research, including clinical trials.

Main Methods:

  • Comprehensive literature review of studies on thymoquinone's anticancer effects.
  • Analysis of TQ's impact on cancer cell proliferation, apoptosis, inflammation, and immune response.
  • Examination of TQ's role in targeting cancer stem cells, the tumor microenvironment, and epigenetic regulation.

Main Results:

  • TQ exhibits anticancer activities including inhibiting proliferation, inducing apoptosis, reducing inflammation, and modulating immune responses.
  • TQ demonstrates potential in overcoming chemoresistance and synergizing with chemotherapy, radiation, and immunotherapy in preclinical models.
  • TQ influences cancer stem cells, the tumor microenvironment, and epigenetic modifications, suggesting broad-spectrum activity.

Conclusions:

  • Thymoquinone (TQ) presents a promising natural compound for cancer therapy with diverse mechanisms of action.
  • Enhancing TQ's bioavailability and conducting clinical trials are essential next steps for its therapeutic development.
  • TQ holds potential to improve cancer treatment efficacy and tolerability, warranting further investigation.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K